

# Clonal Composition and Community Clustering of Drug-Susceptible and -Resistant *Escherichia coli* Isolates from Bloodstream Infections

Sheila Adams-Sapper,<sup>a</sup> Binh An Diep,<sup>b</sup> Francoise Perdreau-Remington,<sup>b</sup> Lee W. Riley<sup>a</sup>

School of Public Health, Division of Infectious Diseases and Vaccinology, University of California, Berkeley, Berkeley, California, USA<sup>a</sup>; Department of Medicine, University of California, San Francisco, San Francisco, California, USA<sup>b</sup>

Multidrug-resistant *Escherichia coli* strains belonging to a single lineage frequently account for a large proportion of extraintestinal *E. coli* infections in many parts of the world. However, limited information exists on the community prevalence and clonal composition of drug-susceptible *E. coli* strains. Between July 2007 and September 2010, we analyzed all consecutively collected Gram-negative bacterial isolates from patients with bloodstream infection (BSI) admitted to a public hospital in San Francisco for drug susceptibility and associated drug resistance genes. The *E. coli* isolates were genotyped for *fimH* single nucleotide polymorphisms (SNPs) and multilocus sequence types (MLSTs). Among 539 isolates, *E. coli* accounted for 249 (46%); 74 (30%) of them were susceptible to all tested drugs, and 129 (52%) were multidrug resistant (MDR). Only five MLST genotypes accounted for two-thirds of the *E. coli* isolates; the most common were ST131 (23%) and ST95 (18%). Forty-seven (92%) of 51 ST131 isolates, as opposed to only 8 (20%) of 40 ST95 isolates, were MDR ( $P < 0.0001$ ). The Simpson's diversity index for drug-susceptible ST genotypes was 87%, while the index for MDR ST genotypes was 81%. ST95 strains were comprised of four *fimH* types, and one of these (*f*-6) accounted for 67% of the 21 susceptible isolates ( $P < 0.003$ ). A large proportion (>70%) of both MDR and susceptible *E. coli* BSI isolates represented community-onset infections. These observations show that factors other than the selective pressures of antimicrobial agents used in hospitals contribute to community-onset extraintestinal infections caused by clonal groups of *E. coli* regardless of their drug resistance.

Recently, much attention has been given to the worldwide dissemination of extraintestinal pathogenic *Escherichia coli* (ExPEC) strains belonging to a related lineage, such as the drug-resistant *E. coli* O25b:H4 multilocus sequence type (MLST) ST131 (1–7). Retrospective studies have shown that from as early as 2000, multidrug-resistant (MDR) ST131 strains were implicated in a large proportion of community-acquired urinary tract infections (UTI) and bloodstream infections (BSI) in different regions of the world (5, 6, 8–10). This global dispersion of ST131 has been suggested to be mediated by activities such as global food trade, international travel, and other modes of transmission (5, 6, 10, 11).

There are other ExPEC strains belonging to a limited number of lineages that circulate globally (2, 4–7, 12, 13). However, most published reports on these lineages have focused on drug-resistant strains. The epidemiologic observation that certain drug-resistant *E. coli* lineages predominate in community and institutional settings is unexplained. One explanation may be that most studies focus on drug-resistant infections and that such study results are more likely to be reported. Another explanation is that drug-resistant strains have selective advantage because of their drug resistance. Finally, it is possible that they become predominant because of epidemiologic or biologic factors unrelated to drug resistance. We reasoned that if drug-susceptible *E. coli* strains are also found to exhibit clonal distribution in community settings, this would indicate that factors other than drug resistance contribute to the clonal spread of ExPEC. This study was undertaken to compare the clonal compositions of drug-resistant and -susceptible *E. coli* clinical isolates from patients with BSI who were treated at a large public hospital in San Francisco.

## MATERIALS AND METHODS

**Strain collection.** The clinical microbiology laboratory of San Francisco General Hospital (SFGH) is one of the largest in the Bay Area, and the

cultures originate from all the hospital wards and jail clinics and San Francisco's city outpatient clinics. All Gram-negative bacillus (GNB) isolates from BSI at the clinical microbiology laboratory of SFGH are stored on agar slants for up to 3 months. Every 3 months, these isolates were provided to us for analysis. We examined all consecutively collected GNB BSI isolates from inpatients admitted to SFGH between July 2007 and September 2010. This study was approved by the University of California, San Francisco, Committee on Human Research.

The information on the dates of admission and first blood culture that yielded the GNB pathogen was available for most of the isolates. In this study, we considered BSI to be community onset if the time period between the date of admission and the date of the first blood culture that grew a GNB pathogen was  $\leq 48$  h.

**Strain identification and susceptibility testing.** At SFGH, the BSI isolates were identified to the species level biochemically with API 20E (bioMérieux, Durham, NC) for fermenters or API 20NE for nonenteric bacteria. Antimicrobial susceptibility tests were performed by a MicroScan WalkAway Gram-negative panel (Dade Behring/Siemens USA, Deerfield, IL). This panel included the following 11 classes of antimicrobial agents (the drugs tested within each): aminoglycosides (amikacin, gentamicin, tobramycin), aminopenicillins (ampicillin),  $\beta$ -lactamase inhibitor combinations (ampicillin-sulbactam, piperacillin-tazobactam, ticarcillin-clavulanic acid), broad-spectrum 1st-generation cephalosporins (cefazolin), broad-spectrum 2nd-generation cephalosporins (cefotetan, cefuroxime, cefoxitin), extended-spectrum 3rd-generation cephalosporins (cefotaxime, ceftriaxone, ceftazidime), extended-spectrum 4th-gen-

Received 16 May 2012 Returned for modification 24 June 2012

Accepted 3 November 2012

Published ahead of print 12 November 2012

Address correspondence to Lee W. Riley, lrwiley@berkeley.edu.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

doi:10.1128/AAC.01025-12

TABLE 1 PCR primers used in this study

Primer target	Primer name <sup>a</sup>	Sequence (5'–3')	Expected product size (bp)	Reference	
Class 1 integrase	201F	CCTCCCGCACGATGATC	280	1	
	202R	TCCACGCATCGTCAGGC			
Class 1 gene cassette, variable region	5' CS	GGCATCCAAGCAGCAAG	Variable	25	
	3' CS	AAGCAGACTTGACCTGA			
<i>fimH</i> SNP	<i>fimH</i> F	TCGAGAACGGATAAGCCGTGG	506	49	
	<i>fimH</i> R	GCAGTCACCTGCCCTCCGGTA			
16S ribosomal DNA, positive control	16S8F	AGAGTTTGATCCTGGCTCAG	800	1	
	16S8R	GGACTACCAGGTATCTAATCC			
ESBL multiplex	MultiTSO-T_for MultiTSO-T_rev	CATTTCCGTGTCGCCCTTATTC	800	7	
		CGTTCATCCATAGTTGCCTGAC			
		AGCCGCTTGAGCAAATTAAC			
SHV variants, including SHV-1	MultiTSO-S_for MultiTSO-S_rev	ATCCCGCAGATAAAATCACCAC	713	7	
		GGCACCAGATTCAACTTTCAAG			
OXA-1, -4, and -30	MultiTSO-O_for MultiTSO-O_rev	GACCCCAAGTTTCTGTAAAGTG	564	7	
CTX-M universal	CTX-M Univ F CTX-M Univ R	TTTGCGATGTGCAGTACCAGTAA	500	45	
		CTCCGCTGCCGTTTTATC			
CTX-M families	CTX-M-1-all F CTX-M-1-all R	ATGGTTAAAAAATCACTGCG	876	45	
		TTACAAAACCGTCGGTGACGAT			
	CTX-M-9-F CTX-M-9-R	GAGATAATACGCAGGTG	392	45	
		CGGCGTGGTGGTGTCTCT			
CTX-M multiplex	Variants including CTX-M-1, -3, and -15	MultiCTXMGp1_for	TTAGGAARTGTGCCGCTGYA	688	7
		MultiCTXMGp1_rev	CGATATCGTTGGTGGTRCCAT		
	Variants including CTX-M-2	MultiCTXMGp2_for MultiCTXMGp2_rev	CGTTAACGGCAGCATGAC	404	7
			CGATATCGTTGGTGGTRCCAT		
	Variants including CTX-M-9 and -14	MultiCTXMGp9_for MultiCTXMGp9_rev	TCAAGCCTGCCGATCTGGT	561	7
TGATTCTCGCCGCTGAAG					
Variants including CTX-M-8, -25, -26, -39, and -41	MultiCTXMGp8_for MultiCTXMGp8_rev	AACRCRCAGACGCTCTAC	326	7	
		TCGAGCCGGAASGTGYAT			
<i>pabB</i>	<i>pabB</i> F <i>pabB</i> R	TCCAGCAGGTGCTGGATCGT	347	3	
		GCGAAATTTTCGCCGTACTGT			

<sup>a</sup> F, forward primer; R, reverse primer.

eration cephalosporins (cefepime), fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin), folate path inhibitors (trimethoprim-sulfamethoxazole), monobactams (aztreonam), and carbapenems (ertapenem, imipenem, meropenem). *E. coli* multidrug resistance (MDR) was defined as resistance to one or more agents in three or more classes of tested drugs (8, 14). Intermediate susceptibility was classified as resistant. Etest (bioMérieux, Marcy l'Etoile, France) was used to confirm susceptibility to carbapenems for select isolates.

**DNA extraction and PCR amplification for gene detection.** The bacterial DNA was extracted by a freeze-boil method, and PCR amplification was carried out as previously described (15). Primer sequences for PCR analysis of *fimH* genotyping,  $\beta$ -lactamase genes, class 1 integron, and associated gene cassettes were used as previously described (Table 1).

**Sequence analysis.** A 5- $\mu$ l aliquot of each PCR product that appeared as a unique band when visualized by gel electrophoresis was cleaned with 2  $\mu$ l of a 1:10 dilution of ExoSAP-IT (Affymetrix, Inc., Santa Clara, CA) and subjected to direct sequencing. Sequencing was done on an Applied Biosystems 3730 DNA analyzer (Applied Biosystems, Foster City, CA) at the University of California, Berkeley, DNA Sequencing Facility. The

DNA sequences were visually inspected, edited, and assembled with BioEdit version 7.0.1. ClustalW was used to perform multiple alignment analyses of the sequences. Sequences were compared with those deposited in the National Center for Biotechnology Information (NCBI) database by an updated version of the BLAST program.

**Genotyping of *E. coli* strains.** We genotyped *E. coli* isolates by two methods. One was a single nucleotide polymorphism (SNP) analysis of the *fimH* locus that encodes a mannose-binding subunit protein located at the tip of type 1 fimbriae, performed according to a previously published report (17). Designation of *fimH* allele types followed the classification system established by Dias et al. (21); the SNP analysis of *fimH* can further discriminate strains genotyped by multilocus sequence typing (MLST). The other method was MLST based on a protocol published on the University College Cork website (<http://mlst.ucc.ie/mlst/>). The MLST analysis is based on sequence comparison of a portion of the following seven housekeeping genes: *adh*, *fumC*, *recA*, *mdh*, *purA*, *gyrB*, and *icd*.

Allele sequences of these genes were submitted to the MLST database curator for sequence type (ST) and sequence complex assignment. Sequence complexes include STs that differ from each other by no more

TABLE 2 Antimicrobial resistance and selected  $\beta$ -lactamase genes identified among BSI *E. coli* isolates

ST (total no. of isolates)	No. (%) of isolates resistant to each class <sup>a</sup>						<i>bla</i> <sub>CTX-M</sub> type(s) (no. of isolates)	No. of isolates with:		<i>bla</i> <sub>KPC</sub> type (no. of isolates)
	QUIN	SXT	CTX	FEP	ATM	CARB		<i>bla</i> <sub>TEM</sub>	<i>bla</i> <sub>OXA-1</sub>	
ST131 (51)	46 (90)	36 (71)	17 (33)	15 (29)	16 (31)	0 (0)	-15 (13), -1 (3), -14 (2)	3	14	
ST95 (40)	1 (3)	7 (18)	1 (3)	1 (3)	2 (5)	0 (0)	-14 (1)	0	0	-2 (1)
ST73 complex (20)	0 (0)	7 (35)	1 (5)	0 (0)	1 (5)	0 (0)				
ST69 (19)	2 (11)	12 (63)	0 (0)	0 (0)	0 (0)	0 (0)				
ST12 complex (13)	0 (0)	9 (69)	3 (23)	3 (23)	3 (23)	0 (0)	-15 (1 <sup>b</sup> ), -14 (2 <sup>b</sup> )	3	0	-2 or -3 (1)
ST10 complex (9)	1 (11)	6 (67)	1 (11)	1 (11)	1 (11)	0 (0)	-15 (1)	1	0	
ST1576 (2)	2 (100)	0 (0)	2 (100)	1 (50)	2 (100)	0 (0)	-15 (1), -14 (1)	0	0	
ST224 (1)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)		0	0	
ST624 (1)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)	0 (0)	-14 (1)	0	1	
ST405 complex (4)	1 (25)	3 (75)	0 (0)	0 (0)	0 (0)	0 (0)				
ST998 (1)	0 (0)	0 (0)	1 (100)	1 (100)	1 (100)	0 (0)		0	0	
ST964 (1)	1 (100)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)		0	0	
ST38 complex (4)	1 (100)	4 (100)	0 (0)	0 (0)	0 (0)	0 (0)		1	0	
Other cluster ST (39) <sup>c</sup>	6 (15)	10 (26)	1 (3)	1 (3)	1 (3)	0 (0)				
Unique ST (15) <sup>c</sup>	0 (0)	1 (7)	0 (0)	0 (0)	0 (0)	0 (0)				
No ST (26)	3 (12)	10 (38)	0 (0)	0 (0)	0 (0)	0 (0)				
All (246)	66 (27)	108 (44)	29 (12)	24 (10)	29 (12)	0 (0)	26 <sup>b</sup>	8	15	2

<sup>a</sup> QUIN, fluoroquinolones; SXT, trimethoprim-sulfamethoxazole; CTX, broad-spectrum cephalosporins (including cefotaxime, ceftazidime, and ceftriaxone); FEP, cefepime; ATM, aztreonam; CARB, carbapenem.

<sup>b</sup> One strain had both *bla*<sub>CTX-M-14</sub> and *bla*<sub>CTX-M-15</sub>.

<sup>c</sup> Cluster ST, 2 or more isolates; unique ST, 1 isolate per group.

than two of the seven loci, as defined by Wirth et al. (22). Strains that were genotyped as ST131 were based on all seven MLST alleles if all of the targets yielded interpretable sequences or a combination of at least three MLST alleles and ST131 allele-specific PCR for the *pabB* gene as established by Clermont et al. (20).

**Statistics.** Categorical variables were compared by a chi-square or Fisher exact test (2-tailed). Genotype diversity was analyzed by Simpson's diversity index (23).

**Nucleotide sequence accession numbers.** The *fimH* gene sequences from this study that were found to be unique (partial coding sequence [CDS] corresponding to the bp positions 360 to 781 of the *E. coli* strain K-12 sequence [GenBank accession number GQ487190]) were deposited in GenBank under accession numbers KC020174 to KC020181.

## RESULTS

**Bacterial species identified from patients with BSI.** Of 539 Gram-negative bacterial BSI isolates collected between July 2007 and September 2010, five species comprised 76% of the population. *E. coli* was the most frequent species with 249 (46%) isolates, followed by 70 (13.0%) *Klebsiella pneumoniae* isolates, 35 (7%) *Proteus mirabilis* isolates, 31 (6%) *Pseudomonas aeruginosa* isolates, and 26 (5%) *Enterobacter cloacae* isolates. This study focuses on the *E. coli* BSI isolates.

**Antimicrobial drug resistance.** Susceptibility results for 11 classes of antimicrobial agents were available for 246 (99%) *E. coli* isolates. The following results are based on these 246 isolates. Among these isolates, 74 (30%) were susceptible to all tested drugs, 43 (17%) were resistant to one or two classes, and 129 (52%) were MDR. Based on the number of discharges from the medical and surgical services of the study hospital in the study period of 2007 to 2010 (average of 12,200/year), the incidence (per 1,000 discharges/year) was estimated to be 6.1 for *E. coli* BSI, 1.9 for drug-susceptible *E. coli* BSI, and 3.2 for MDR *E. coli* BSI. The susceptibility results for isolates in the study period were reported

prior to the 2010 Clinical and Laboratory Standards Institute (CLSI) antimicrobial susceptibility breakpoint changes for carbapenems, cephalosporins, and aztreonam. All isolates were susceptible to ertapenem, imipenem, and meropenem, 29 (12%) were resistant to aztreonam, 108 (44%) were resistant to trimethoprim-sulfamethoxazole, 66 (27%) were resistant to fluoroquinolones, 29 (12%) were resistant to cefotaxime, ceftazidime, and ceftriaxone, and 24 (10%) were resistant to cefepime (Table 2). All 25 CTX-M gene-positive isolates were MDR, comprising 19% of the 129 MDR *E. coli* isolates, and were significantly more likely to be MDR than other drug-resistant strains ( $P < 0.0001$ ).

**Identification of genotypes by MLST and *fimH* sequence analysis.** MLST was done to genotype 220 (89%) isolates, which fell into 41 distinct STs or ST complexes. MLST results were not able to be obtained for 26 (11%) isolates due to repeated failure of PCR amplification or interpretable sequence results of an insufficient number of the seven alleles to place them in a ST complex. Only five STs accounted for 143 (65%) of 220 typed *E. coli* BSI isolates (Table 3). ST131 comprised the largest ST cluster with 51 (23%) isolates, followed by ST95 identified in 40 (18%) isolates. Others included the ST73 complex with 20 (8%) isolates, ST69 with 19 (9%), and the ST12 complex with 13 (6%).

Of 246 *E. coli* isolates, 236 (96%) had the *fimH* gene, comprised of 34 different *fimH* SNP types (17, 21). Only three *fimH* types (*f*-1, -6, and -9) accounted for 138 (58%) of 236 typed *E. coli* isolates; 115 (83%) of these belonged to the five most frequently detected STs (Table 4). The three most frequent *fimH* types comprised 49 (96%) of the ST131 isolates, 36 (90%) of the ST95 isolates, 19 (100%) of the ST69 isolates, 4 (20%) of the ST73 complex isolates, and 7 (54%) of the ST12 complex isolates. The eight most prevalent STs contained from one to five *fimH* types, with one or two types found to be dominant per ST (Table 3). Strains containing

TABLE 3 Distribution of *E. coli* genotypes by MLST

MLST	No. (%) of isolates that are:			P value <sup>c</sup>	Total no. (%) of isolates typed <sup>d</sup>	<i>fimH</i> type(s)	Dominant <i>f</i> -type (no. in each type [% of total])
	Susceptible	Resistant <sup>a</sup>	MDR <sup>b</sup>				
ST131	0 (0)	4 (8)	47 (92)	<0.0005	51 (23)	<i>f</i> -1, -6, -9, -11, -17	<i>f</i> -9 (44 [86])
ST95	21 (53)	11 (27)	8 (20)	0.001	40 (18)	<i>f</i> -1, -6, -9, -47	<i>f</i> -6 (17[43]), <i>f</i> -1 (16[40])
ST73 complex	6 (30)	7 (35)	7 (35)	0.806	20 (8)	<i>f</i> -3, -8, -9, -60	<i>f</i> -8 (12[52])
ST69	3 (16)	4 (21)	12 (63)	0.198	19 (9)	<i>f</i> -1	<i>f</i> -1 (19[100])
ST12 complex	1 (8)	1 (8)	11 (84)	0.116	13 (6)	<i>f</i> -1, -6, -51, -52	<i>f</i> -1 (6[46])
ST10 complex	2 (22)	1 (11)	6 (67)	1.0	9 (4)	<i>f</i> -1, -4, -6, -20, -28	<i>f</i> -6 (3[33])
ST38 complex	0 (0)	0 (0)	4 (100)	0.319	4 (2)	<i>f</i> -12, -57	<i>f</i> -12 (3[75])
ST405 complex	0 (0)	0 (0)	4 (100)	0.319	4 (2)	<i>f</i> -1, -4	<i>f</i> -1 (2[50])
ST127	2 (67)	1 (33)	0 (0)	0.216	3 (1)	<i>f</i> -2	<i>f</i> -2 (3[100])
ST1278	0 (0)	3 (50)	3 (50)	0.182	6 (2)	<i>f</i> -9	<i>f</i> -9 (6[100])
ST14 complex	0 (0)	2 (67)	1 (33)	0.556	3 (1)	<i>f</i> -1, -9	<i>f</i> -1 (2[67])
ST144	2 (67)	0 (0)	1 (33)	0.216	3 (1)	<i>f</i> -4	<i>f</i> -4 (3[100])
ST155 complex	3 (100)	0 (0)	0 (0)	0.026	3 (1)	<i>f</i> -7	<i>f</i> -7 (3[100])
ST23 complex	1 (33)	1 (33)	1 (33)	1.0	3 (1)	<i>f</i> -1, -6	<i>f</i> -6 (2[67])
ST31 complex	0 (0)	1 (25)	3 (75)	0.556	4 (2)	<i>f</i> -4	<i>f</i> -4 (4[100])
ST372	3 (100)	0 (0)	0 (0)	0.026	3 (1)	<i>f</i> -3	<i>f</i> -3 (3[100])
ST1841	0 (0)	0 (0)	2 (100)	1.0	2 (1)	<i>f</i> -7	<i>f</i> -7 (2[100])
ST1576	0 (0)	0 (0)	2 (100)	1.0	2 (1)	<i>f</i> -1	<i>f</i> -1 (2[100])
ST420	2 (100)	0 (0)	0 (0)	0.09	2 (1)	<i>f</i> -29	<i>f</i> -29 (2[100])
ST568 complex	2 (100)	0 (0)	0 (0)	0.09	2 (1)	<i>f</i> -2	<i>f</i> -2 (2[100])
ST62	0 (0)	1 (50)	1 (50)	1.0	2 (1)	<i>f</i> -5	<i>f</i> -5 (2[100])
ST59 complex	2 (67)	0 (0)	1 (33)	0.512	3 (1)	<i>f</i> -47, 2 NT <sup>e</sup>	<i>f</i> -47 (1[50])
Unique ST	12 (63)	2 (11)	5 (26)	0.001	19 (9)	<i>f</i> -1, -2, -3, -5, -7, -13, -27, -39, -49, -50, -59	<i>f</i> -7 (4[21])
Total isolates typed	62 (28)	39 (18)	119 (54)		220		
Not typed	12 (46)	4 (15)	10 (39)		26		
Total	74 (30)	43 (17)	129 (52)		246		

<sup>a</sup> Resistant to one or two classes of drugs.<sup>b</sup> Resistant to three or more classes of drugs.<sup>c</sup> P value compares the susceptible column and any resistance.<sup>d</sup> % of those typed by MLST ( $n = 220$ ).<sup>e</sup> NT, not typed.

the *f*-9 type were more likely to be MDR ( $P = 0.001$ ), and 44 (86%) of them were ST131, while strains containing the *f*-6 type were more likely to be susceptible ( $P = 0.02$ ) and 17 (43%) of them were ST95.

*fimH* SNP types were used to further differentiate ST95 strains. ST95 strains were comprised of 4 *fimH* SNP types (*f*-1, -6, -9, and -47). Fourteen (67%) of the 21 drug-susceptible ST95 strains belonged to one *fimH* SNP type (*f*-6), whereas 16 (84%) of 19 resistant ST95 strains belonged to three other *fimH* types ( $P = 0.003$ ) (Fig. 1). The *f*-6 type was the most prevalent SNP type, accounting for 17 (43%) of the ST95 strains. None of these were MDR ( $P < 0.05$ ). The *f*-1 type comprised 16 (40%) of the ST95 strains, and 12 (75%) of these were resistant to at least one class of antimicrobial agents while 6 (38%) were MDR ( $P > 0.05$ ). The *f*-9 and *f*-47 types comprised 3 and 4 ST95 strains, respectively, with one MDR strain in each.

**Diversity of genotypes.** Among 220 *E. coli* isolates typed by MLST, 41 STs or ST complexes were identified. Of these, 201 (91%) belonged to one of 22 ST groups (Table 5). Nineteen isolates belonged to unique STs. Simpson's diversity index for all STs was 89% (95% confidence interval [CI], 86% to 91%). The index for drug-susceptible ST genotypes was 87% (95% CI, 80% to 94%), while the index for MDR ST genotypes was 81% (95% CI,

74% to 87%). The index for any drug-resistant (MDR and resistance to one or two classes of drug) ST genotypes was 85% (95% CI, 81% to 89%). A higher index represents greater diversity.

Three of the five most prevalent *E. coli* clonal groups, ST131, ST69, and ST12 complex, were significantly more likely to be MDR than were others ( $P = 0.047$ ). These three clonal groups comprised 70 (54%) of the MDR strains (Table 3). The other MDR strains were comprised of 19 distinct STs (10 strains were not typed). On the other hand, ST95 strains were more likely to be susceptible ( $P = 0.001$ ). In fact, drug-susceptible strains belonging to this clonal group accounted for 28% of all 74 drug-susceptible isolates in the study. Of 119 typed MDR *E. coli* strains, 114 (96%) belonged to one of 17 STs represented by 2 or more members per ST. Of 62 typed susceptible strains, 50 (81%) belonged to one of 13 STs represented by 2 or more members per ST. A large proportion (63%) of the 19 unique STs were fully susceptible.

**Distribution of  $\beta$ -lactamase genes.** The *bla*<sub>CTX-M</sub> gene was detected among 25 (10%) *E. coli* strains in five ST groups and only one nonclonal ST (Table 2). Fifteen had *bla*<sub>CTX-M-15</sub> (group 1), 6 had *bla*<sub>CTX-M-14</sub> (group 9), and one (an ST12 complex isolate) had both. For three strains with the *bla*<sub>CTX-M-1</sub> group gene, CTX-M variants were not able to be further differentiated. ST131 accounted for 18 (72%) of the 25 isolates carrying *bla*<sub>CTX-M</sub>. Two

TABLE 4 Distribution of *E. coli* genotypes by *fimH* SNP analysis

<i>fimH</i> type <sup>a</sup>	No. (%) of isolates that are:			<i>P</i> value <sup>d</sup>	No. (%) of isolates among 5 most prevalent STs	Total no. of <i>fimH</i> type isolates
	Susceptible	Resistant <sup>b</sup>	MDR <sup>c</sup>			
<b><i>f-1</i></b>	10 (19)	13 (24)	31 (57)	0.024	<b>43 (80)</b>	<b>54</b>
<i>f-2</i>	7 (88)	1 (13)	0 (0)	0.001		8
<i>f-3</i>	6 (75)	0 (0)	2 (25)	0.01	3 (38)	8
<i>f-4</i>	3 (27)	1 (9)	7 (64)	1.0		11
<i>f-5</i>	0 (0)	1 (25)	3 (75)	0.319		4
<b><i>f-6</i></b>	14 (54)	4 (15)	8 (31)	0.005	<b>21 (81)</b>	<b>26</b>
<i>f-7</i>	7 (78)	0 (0)	2 (22)	0.004		9
<i>f-8</i>	2 (17)	6 (50)	4 (33)	0.519	12 (100)	12
<b><i>f-9</i></b>	4 (7)	9 (16)	45 (77)	<0.0005	<b>51 (88)</b>	<b>58</b>
<i>f-10</i>	1 (33)	0 (0)	2 (67)	0.512		3
<i>f-11</i>	1 (50)	0 (0)	1 (50)	0.512	1 (50)	2
<i>f-12</i>	0 (0)	0 (0)	3 (100)	0.556		3
<i>f-13</i>	1 (25)	1 (25)	2 (50)	0.556		4
<i>f-27</i>	2 (100)	0 (0)	0 (0)	0.09		2
<i>f-29</i>	2 (100)	0 (0)	0 (0)	0.09		2
<i>f-47</i>	2 (40)	2 (40)	1 (20)	0.638	4 (80)	5
<i>f-51</i>	2 (33)	1 (17)	3 (50)	1.0	4 (67)	6
<i>f-52</i>	0 (0)	0 (0)	2 (100)	1.0	2 (100)	2
<i>f-53</i>	2 (100)	0 (0)	0 (0)	0.09		2
Unique <i>f</i> -type	4 (27)	3 (20)	8 (53)	1.0	2 (13)	15
Total typed	70 (30)	42 (18)	124 (52)			236
Total untyped	4 (40)	1 (10)	5 (50)		0 (0)	10
Total	74 (30)	43 (17)	129 (52)		143 (58)	246

<sup>a</sup> *fimH* types (*f*-types) in bold are the three most prevalent *fimH* SNP types.

<sup>b</sup> Resistant to one or two classes of drugs.

<sup>c</sup> Resistant to three or more classes of drugs.

<sup>d</sup> *P* value compares the susceptible column and any resistance.

carried *bla*<sub>CTX-M-14</sub> and 16 had *bla*<sub>CTX-M-1</sub> group genes, of which 13 were *bla*<sub>CTX-M-15</sub>. Fifteen CTX-M gene-positive isolates also had *bla*<sub>OXA-1</sub>. PCR analysis of *bla*<sub>TEM</sub> and *bla*<sub>SHV</sub> was performed on 36 *E. coli* isolates. Three ST131 isolates were *bla*<sub>TEM</sub> gene positive by PCR, and two of these coharbored *bla*<sub>CTX-M</sub>. Isolates carrying *bla*<sub>TEM</sub> were also found among three ST12 complex isolates and one each of ST10 complex and ST38 complex isolates. Only one of 40 ST95 isolates was extended-spectrum β-lactamase (ESBL) gene positive. This strain was resistant to cefotaxime and carried *bla*<sub>CTX-M-14</sub> and *bla*<sub>KPC</sub>. One ST12 complex isolate was also found to carry both *bla*<sub>CTX-M-14</sub> and *bla*<sub>KPC</sub>. Both KPC gene-positive isolates were sensitive to all carbapenems tested. Susceptibility to imipenem and ertapenem was confirmed by Etest, with MICs for both strains of 0.25 and 0.023 for imipenem and ertapenem, respectively. No ESBL genes were found among the ST69 or ST73 complex strains. The *bla*<sub>SHV</sub> gene was not detected in any of the tested strains.

**Strain distribution by time of first positive blood culture results.** Of 244 (99%) *E. coli* isolates with known time of first positive blood culture results, 198 (81%) were cultured from blood <48 h after patient admission (Table 6). Most of the cultures were done at the emergency department (ED) before admission. Among 73 fully susceptible and 128 MDR isolates with culture result data, 62 (85%) and 101 (79%), respectively, were isolated from blood <48 h after patient admission (*P* > 0.05). Large proportions (>70%) of each of the 5 most common ST strains were isolated from blood <48 h after patient admission. Based on the


number of ED visits during the study period, the incidences of susceptible *E. coli* BSI and MDR *E. coli* BSI were 0.12 and 0.30 per 1,000 ED visits, respectively (*P* > 0.05).

## DISCUSSION

Of 246 *E. coli* isolates consecutively collected from patients with BSI in one San Francisco hospital over a 3-year period, we found that only five genotypes by MLST accounted for 146 (66%) of the typed *E. coli* isolates; these were ST131, ST95, ST73 complex, ST69, and ST12 complex. Interestingly, MDR strains belonging to ST131 and ST69 accounted for nearly half (46%) of all MDR isolates while drug-susceptible strains from ST95 and ST73 complex accounted for more than one-third (36%) of all drug-susceptible strains in this study. Thus, both MDR and drug-susceptible *E. coli* strains have clonal distribution and accounted for a large proportion of bloodstream isolates from patients admitted to a public hospital in San Francisco.

All of these STs, with the exception of ST69, which belongs to phylogenetic group D, are reported to belong to phylogenetic group B2. Both phylogenetic groups are typically associated with human ExPEC infections (13, 24, 25). Strains belonging to these clonal groups are also frequently isolated from food-producing and companion animals and from retail meats (10, 11, 26–35) and cause serious infections in otherwise healthy individuals (6, 13). Isolates of the enterobacterial repetitive intergenic consensus 2 (ERIC-2) PCR pattern CgA, later characterized as ST69 by MLST, were the most common uropathogenic *E. coli* genotype isolated

## SUSCEPTIBLE STRAINS



## RESISTANT STRAINS



## MDR STRAINS




FIG 1 Distribution of *fimH* SNP types among ST95 strains by drug susceptibility.

from college students with UTI (36, 37). ST95 contains members of avian pathogenic *E. coli* (APEC) as well as human uropathogenic *E. coli* (UPEC) and neonatal meningitis *E. coli* (NMEC) (25). ST95 subgroups share common serotypes and virulence factors, including carriage of *pap* genes encoding P-type fimbriae which enhance colonization in avian and human epithelial cells. These characteristics may promote an opportunity for zoonotic transmission (38–41).

ST131, the most prevalent MLST genotype reported globally, was also the most common ST found in this study, accounting for 51 (23%) of typed *E. coli* isolates, 47 (36%) of all MDR isolates, and 18 (72%) of CTX-M gene-positive isolates. This clonal group was comprised of five *fimH* SNP types, for which 39 (76%) strains

TABLE 6 Distribution of *E. coli* MLSTs by timing of the first collection of blood culture that grew *E. coli*

ST or ST complex	No. (%) of isolates for each collection time	
	>48 h	<48 h
ST131	14 (27)	37 (73)
ST95 <sup>a</sup>	4 (10)	36 (90)
ST73 complex	4 (20)	16 (80)
ST69 <sup>a</sup>	3 (17)	15 (83)
ST12 complex <sup>a</sup>	1 (8)	11 (92)
Other STs <sup>a</sup>	13 (18)	61 (82)
Untyped	6 (23)	20 (77)
Total <sup>a</sup>	46 (19)	198 (81)

<sup>a</sup> Data on the timing of the first positive isolate collection are available for 244 of 249 *E. coli* isolates.

were *f*-9, and all but four of these were MDR. A large proportion of these ST131 infections appear to be community onset, since the blood cultures of 37 (73%) isolates grew *E. coli* within 48 h of hospital admission. This clonal group has worldwide distribution as a common cause of UTI and BSI (3–6, 42). ST131 is remarkable for its carriage of a wide array of virulence factors (8, 10, 43, 44) in addition to being a major producer of CTX-M-type ESBLs (1, 2, 7, 9, 10) and, more recently, for its acquisition of the carbapenemase-encoding genes *bla*<sub>KPC</sub>, *bla*<sub>VIM</sub>, and *bla*<sub>NDM-1</sub> (45–48). These drug resistance determinants are often located on plasmids and associated with integrons and IS elements (3, 10, 49–51). A recent report found that by pulsed-field gel electrophoresis (PFGE), ST131 strains isolated from human clinical sources belonged to pulsotypes distinct from those obtained from foods or animal food sources (52).

ST95 was the second largest clonal group identified in this study. Unlike ST131, the majority (53%) were susceptible to all tested antimicrobial agents. Like ST131, a large proportion (90%) of ST95 isolates were classified as representing community-onset infection. ST95 was found in our study population with prevalence nearly equal to that of ST131 in spite of having significantly fewer drug-resistant strains ( $P = 0.001$ ). In fact, among four *fimH* SNP types comprising ST95, one (*f*-6) was responsible for most (67%) of the drug-susceptible strains. Such an observation suggests that drug resistance is not a prerequisite for clonal dissemination.

The observation that drug-susceptible ST95 disseminates clonally is not new. Manges et al. found several ST95 isolates in their report of endemic and epidemic lineages of *E. coli* causing UTI in

TABLE 5 Simpson's diversity index by MLST and by antimicrobial resistance status

Resistance level (no. of isolates)	No. (%) of isolates MLST typed	No. of MLST cluster types	No. (%) of isolates in MLST cluster types <sup>a</sup>	No. of isolates in MLST unique types <sup>a</sup>	Simpson's diversity index (%) (95% CI)
Susceptible (74)	62 (84)	13	50 (81)	12	87 (80–94)
Resistant (43) <sup>b</sup>	39 (91)	12	37 (95)	2	86 (80–93)
MDR (129) <sup>c</sup>	119 (92)	17	114 (96)	5	81 (74–87)
Any resistance (172) <sup>d</sup>	154 (90)	18	147 (95)	7	85 (81–89)
All <i>E. coli</i> isolates (246)	220 (89)	22	201 (91)	19	89 (86–91)

<sup>a</sup> Cluster, 2 or more isolates; unique, 1 isolate per group.

<sup>b</sup> Resistant to 1 or 2 antimicrobial agents.

<sup>c</sup> Multidrug resistant ( $\geq 3$  classes).

<sup>d</sup> Resistance to  $\geq 1$  class.

Montreal and California (13). All except one of the strains were susceptible to all drugs tested. Vincent et al. detected ST95 in human clinical isolates and in one case of ready-to-eat food product (11). All but two of these isolates were susceptible. ST95 was found to be the most prevalent cause of bacterial peritonitis and BSI in France (24). All ST95 strains isolated from UTI in a study in the northwest of England were susceptible to all tested antimicrobial agents (12). Our study, based on consecutively collected, population-based samples from one large hospital, confirms that drug-susceptible *E. coli* strains can disseminate clonally in community settings.

Near the end of the study period (April 2010), one ST95 isolate collected from a patient within 48 h of admission carried both *bla*<sub>CTX-M</sub> and *bla*<sub>KPC</sub>, which, to our knowledge, is the first example of acquisition of these genes by ST95. This ST95 isolate, an *f-1 fimH* SNP type, was distinct from the other ST95 isolates in that it was resistant to 12 drugs within nine classes of antimicrobial agents and harbored the *dfra17* and *bla*<sub>CTX-M-14</sub> genes. No ESBL genes were found among any of 19 ST69 strains, while more than two-thirds of 25 CTX-M gene-positive strains belonged to ST131. These observations suggest intrinsic differences in the frequency of distinct *E. coli* lineages acquiring different types of mobile drug resistance genes or that these genes remain within the lineages after their “founder” strains acquire them.

Because we consecutively collected and analyzed all BSI isolates from one hospital in San Francisco over a period of 3 years, we were able to determine the relative proportion of infections caused by major clonal groups of both drug-resistant and -susceptible strains. Strain diversity was higher in drug-susceptible strains than in MDR strains, but some of the drug-susceptible strains were indeed clonal by MLST, by *fimH* SNP type, and by both combined. Furthermore, more than two-thirds of MDR as well as drug-susceptible *E. coli* infections were found to have community onset. We do not have additional information about prior health care exposures of these patients, so it is possible that some of these community-onset BSI cases had contact with health care settings prior to their infection. Our observation, of course, is limited to one geographic setting, and thus, a similar study should be performed at other sites to determine the generalizability of our findings. Nevertheless, our data suggest that the overrepresentation of both MDR and susceptible *E. coli* strains causing community-onset BSI may be explained by their enhanced capacity to cause extraintestinal infection rather than selection by antimicrobial agents used in hospitals.

## ACKNOWLEDGMENTS

We thank Michael Jula, Li Basuino, and Patricia Denn of San Francisco General Hospital for assistance with data analyses and arranging to provide the study isolates. We thank Satowa Suzuki, Sara Tartof, Hillary Beriman, and Julian Schmidt for assistance with protocols. We thank Shantell Nolen, Pooja Jael, and Roxane Raphael for technical support.

This study was supported in part by NIH grant AI059523.

All authors declare no conflict of interest.

## REFERENCES

- Coque TM, Novais A, Carattoli A, Poirel L, Pitout J, Peixe L, Baquero F, Canton R, Nordmann P. 2008. Dissemination of clonally related *Escherichia coli* strains expressing extended-spectrum beta-lactamase CTX-M-15. *Emerg. Infect. Dis.* 14:195–200.
- Fam N, Leflon-Guibout V, Fouad S, Aboul-Fadl L, Marcon E, Desouky D, El-Defrawy I, Abou-Aitta A, Klena J, Nicolas-Chanoine MH. 2011. CTX-M-15-producing *Escherichia coli* clinical isolates in Cairo (Egypt), including isolates of clonal complex ST10 and clones ST131, ST73, and ST405 in both community and hospital settings. *Microb. Drug Resist.* 17:67–73.
- Naseer U, Haldorsen B, Tofteland S, Hegstad K, Scheutz F, Simonsen GS, Sundsfjord A. 2009. Molecular characterization of CTX-M-15-producing clinical isolates of *Escherichia coli* reveals the spread of multi-drug-resistant ST131 (O25:H4) and ST964 (O102:H6) strains in Norway. *APMIS* 117:526–536.
- Pitout JD, Church DL, Gregson DB, Chow BL, McCracken M, Mulvey MR, Laupland KB. 2007. Molecular epidemiology of CTX-M-producing *Escherichia coli* in the Calgary Health Region: emergence of CTX-M-15-producing isolates. *Antimicrob. Agents Chemother.* 51:1281–1286.
- Pitout JD, Gregson DB, Campbell L, Laupland KB. 2009. Molecular characteristics of extended-spectrum- $\beta$ -lactamase-producing *Escherichia coli* isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. *Antimicrob. Agents Chemother.* 53:2846–2851.
- Rogers BA, Sidjabat HE, Paterson DL. 2011. *Escherichia coli* O25b-ST131: a pandemic, multiresistant, community-associated strain. *J. Antimicrob. Chemother.* 66:1–14.
- Suzuki S, Shibata N, Yamane K, Wachino J, Ito K, Arakawa Y. 2009. Change in the prevalence of extended-spectrum-beta-lactamase-producing *Escherichia coli* in Japan by clonal spread. *J. Antimicrob. Chemother.* 63:72–79.
- Johnston JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. 2010. *Escherichia coli* sequence type ST131 as the major cause of serious multidrug-resistant *E. coli* infections in the United States. *Clin. Infect. Dis.* 51:286–294.
- Peirano G, Pitout JD. 2010. Molecular epidemiology of *Escherichia coli* producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. *Int. J. Antimicrob. Agents* 35:316–321.
- Platell JL, Johnson JR, Cobbold RN, Trott DJ. 2011. Multidrug-resistant extraintestinal pathogenic *Escherichia coli* of sequence type ST131 in animals and foods. *Vet. Microbiol.* 153:99–108.
- Vincent C, Boerlin P, Daignault D, Dozois CM, Dutil L, Galanakis C, Reid-Smith RJ, Tellier PP, Tellis PA, Ziebell K, Manges AR. 2010. Food reservoir for *Escherichia coli* causing urinary tract infections. *Emerg. Infect. Dis.* 16:88–95.
- Lau SH, Reddy S, Cheesbrough J, Bolton FJ, Willshaw G, Cheasty T, Fox AJ, Upton M. 2008. Major uropathogenic *Escherichia coli* strain isolated in the northwest of England identified by multilocus sequence typing. *J. Clin. Microbiol.* 46:1076–1080.
- Manges AR, Tabor H, Tellis P, Vincent C, Tellier PP. 2008. Endemic and epidemic lineages of *Escherichia coli* that cause urinary tract infections. *Emerg. Infect. Dis.* 14:1575–1583.
- Marquez C, Labbate M, Raymondo C, Fernandez J, Gestal AM, Holley M, Borthagaray G, Stokes HW. 2008. Urinary tract infections in a South American population: dynamic spread of class 1 integrons and multidrug resistance by homologous and site-specific recombination. *J. Clin. Microbiol.* 46:3417–3425.
- Ajiboye RM, Solberg OD, Lee BM, Raphael E, Debroy C, Riley LW. 2009. Global spread of mobile antimicrobial drug resistance determinants in human and animal *Escherichia coli* and *Salmonella* strains causing community-acquired infections. *Clin. Infect. Dis.* 49:365–371.
- Levesque C, Piche L, Larose C, Roy PH. 1995. PCR mapping of integrons reveals several novel combinations of resistance genes. *Antimicrob. Agents Chemother.* 39:185–191.
- Tartof SY, Solberg OD, Riley LW. 2007. Genotypic analyses of uropathogenic *Escherichia coli* based on *fimH* single nucleotide polymorphisms (SNPs). *J. Med. Microbiol.* 56:1363–1369.
- Dallenne C, Da Costa A, Decre D, Favier C, Arlet G. 2010. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. *J. Antimicrob. Chemother.* 65:490–495.
- Shibata N, Kurokawa H, Doi Y, Yagi T, Yamane K, Wachino J, Suzuki S, Kimura K, Ishikawa S, Kato H, Ozawa Y, Shibayama K, Kai K, Konda T, Arakawa Y. 2006. PCR classification of CTX-M-type  $\beta$ -lactamase genes identified in clinically isolated gram-negative bacilli in Japan. *Antimicrob. Agents Chemother.* 50:791–795.
- Clermont O, Dhanji H, Upton M, Gibreel T, Fox A, Boyd D, Mulvey MR, Nordmann P, Ruppe E, Sarthou JL, Frank T, Vimont S, Arlet G, Branger C, Woodford N, Denamur E. 2009. Rapid detection of the

- O25b-ST131 clone of *Escherichia coli* encompassing the CTX-M-15-producing strains. *J. Antimicrob. Chemother.* 64:274–277.
21. Dias RC, Moreira BM, Riley LW. 2010. Use of *fimH* single-nucleotide polymorphisms for strain typing of clinical isolates of *Escherichia coli* for epidemiologic investigation. *J. Clin. Microbiol.* 48:483–488.
  22. Wirth T, Falush D, Lan R, Colles F, Mensa P, Wieler LH, Karch H, Reeves PR, Maiden MC, Ochman H, Achtman M. 2006. Sex and virulence in *Escherichia coli*: an evolutionary perspective. *Mol. Microbiol.* 60:1136–1151.
  23. Simpson EH. 1949. Measurement of diversity. *Nature* 163:688.
  24. Bert F, Johnson JR, Ouattara B, Leflon-Guibout V, Johnston B, Marcon E, Valla D, Moreau R, Nicolas-Chanoine MH. 2010. Genetic diversity and virulence profiles of *Escherichia coli* isolates causing spontaneous bacterial peritonitis and bacteremia in patients with cirrhosis. *J. Clin. Microbiol.* 48:2709–2714.
  25. Johnson JR, Russo TA. 2005. Molecular epidemiology of extraintestinal pathogenic (uropathogenic) *Escherichia coli*. *Int. J. Med. Microbiol.* 295:383–404.
  26. Ewers C, Grobbel M, Stamm I, Kopp PA, Diehl I, Semmler T, Fruth A, Beutlich J, Guerra B, Wieler LH, Guenther S. 2010. Emergence of human pandemic O25:H4-ST131 CTX-M-15 extended-spectrum-beta-lactamase-producing *Escherichia coli* among companion animals. *J. Antimicrob. Chemother.* 65:651–660.
  27. Hannah EL, Johnson JR, Angulo F, Haddadin B, Williamson J, Samore MH. 2009. Molecular analysis of antimicrobial-susceptible and -resistant *Escherichia coli* from retail meats and human stool and clinical specimens in a rural community setting. *Foodborne Pathog. Dis.* 6:285–295.
  28. Johnson JR, Delavari P, O'Bryan TT, Smith KE, Tatini S. 2005. Contamination of retail foods, particularly turkey, from community markets (Minnesota, 1999–2000) with antimicrobial-resistant and extraintestinal pathogenic *Escherichia coli*. *Foodborne Pathog. Dis.* 2:38–49.
  29. Johnson JR, McCabe JS, White DG, Johnston B, Kuskowski MA, McDermott P. 2009. Molecular analysis of *Escherichia coli* from retail meats (2002–2004) from the United States National Antimicrobial Resistance Monitoring System. *Clin. Infect. Dis.* 49:195–201.
  30. Johnson TJ, Logue CM, Wannemuehler Y, Kariyawasam S, Doetkott C, DeRoy C, White DG, Nolan LK. 2009. Examination of the source and extended virulence genotypes of *Escherichia coli* contaminating retail poultry meat. *Foodborne Pathog. Dis.* 6:657–667.
  31. Leverstein-van Hall MA, Dierix CM, Cohen Stuart J, Voets GM, van den Munckhof MP, van Essen-Zandbergen A, Platteeuw T, Fluit AC, van de Sande-Bruinsma N, Scharinga J, Bonten MJ, Mevius DJ. 2011. Dutch patients, retail chicken meat and poultry share the same ESBL genes, plasmids and strains. *Clin. Microbiol. Infect.* 17:873–880.
  32. Manges AR, Smith SP, Lau BJ, Nuval CJ, Eisenberg JN, Dietrich PS, Riley LW. 2007. Retail meat consumption and the acquisition of antimicrobial resistant *Escherichia coli* causing urinary tract infections: a case-control study. *Foodborne Pathog. Dis.* 4:419–431.
  33. Ramchandani M, Manges AR, DeRoy C, Smith SP, Johnson JR, Riley LW. 2005. Possible animal origin of human-associated, multidrug-resistant, uropathogenic *Escherichia coli*. *Clin. Infect. Dis.* 40:251–257.
  34. Randall LP, Clouting C, Horton RA, Coldham NG, Wu G, Clifton-Hadley FA, Davies RH, Teale CJ. 2011. Prevalence of *Escherichia coli* carrying extended-spectrum beta-lactamases (CTX-M and TEM-52) from broiler chickens and turkeys in Great Britain between 2006 and 2009. *J. Antimicrob. Chemother.* 66:86–95.
  35. Xia X, Meng J, McDermott PF, Zhao S. 2011. *Escherichia coli* from retail meats carry genes associated with uropathogenic *Escherichia coli*, but are weakly invasive in human bladder cell culture. *J. Appl. Microbiol.* 110:1166–1176.
  36. Manges AR, Johnson JR, Foxman B, O'Bryan TT, Fullerton KE, Riley LW. 2001. Widespread distribution of urinary tract infections caused by a multidrug-resistant *Escherichia coli* clonal group. *N. Engl. J. Med.* 345:1007–1013.
  37. Smith SP, Manges AR, Riley LW. 2008. Temporal changes in the prevalence of community-acquired antimicrobial-resistant urinary tract infection affected by *Escherichia coli* clonal group composition. *Clin. Infect. Dis.* 46:689–695.
  38. Ewers C, Antao EM, Diehl I, Philipp HC, Wieler LH. 2009. Intestine and environment of the chicken as reservoirs for extraintestinal pathogenic *Escherichia coli* strains with zoonotic potential. *Appl. Environ. Microbiol.* 75:184–192.
  39. Ewers C, Li G, Wilking H, Kiessling S, Alt K, Antao EM, Laturus C, Diehl I, Glodde S, Homeier T, Bohnke U, Steinruck H, Philipp HC, Wieler LH. 2007. Avian pathogenic, uropathogenic, and newborn meningitis-causing *Escherichia coli*: how closely related are they? *Int. J. Med. Microbiol.* 297:163–176.
  40. Johnson TJ, Wannemuehler Y, Johnson SJ, Stell AL, Doetkott C, Johnson JR, Kim KS, Spanjaard L, Nolan LK. 2008. Comparison of extraintestinal pathogenic *Escherichia coli* strains from human and avian sources reveals a mixed subset representing potential zoonotic pathogens. *Appl. Environ. Microbiol.* 74:7043–7050.
  41. Mora A, Lopez C, Dabhi G, Blanco M, Blanco JE, Alonso MP, Herrera A, Mamani R, Bonacorsi S, Moulin-Schouleur M, Blanco J. 2009. Extraintestinal pathogenic *Escherichia coli* O1:K1:H7/NM from human and avian origin: detection of clonal groups B2 ST95 and D ST59 with different host distribution. *BMC Microbiol.* 9:132.
  42. Croxall G, Hale J, Weston V, Manning G, Cheetham P, Achtman M, McNally A. 2011. Molecular epidemiology of extraintestinal pathogenic *Escherichia coli* isolates from a regional cohort of elderly patients highlights the prevalence of ST131 strains with increased antimicrobial resistance in both community and hospital care settings. *J. Antimicrob. Chemother.* 66:2501–2508.
  43. Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG. 2009. Epidemic clonal groups of *Escherichia coli* as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. *Antimicrob. Agents Chemother.* 53:2733–2739.
  44. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, Demarty R, Alonso MP, Canica MM, Park YJ, Lavigne JP, Pitout J, Johnson JR. 2008. Intercontinental emergence of *Escherichia coli* clone O25:H4-ST131 producing CTX-M-15. *J. Antimicrob. Chemother.* 61:273–281.
  45. Mantengoli E, Luzzaro F, Pecile P, Ceconi D, Cavallo A, Attala L, Bartoloni A, Rossolini GM. 2011. *Escherichia coli* ST131 producing extended-spectrum beta-lactamases plus VIM-1 carbapenemase: further narrowing of treatment options. *Clin. Infect. Dis.* 52:690–691.
  46. Morris D, Boyle F, Ludden C, Condon I, Hale J, O'Connell N, Power L, Boo TW, Dhanji H, Lavalley C, Woodford N, Cormican M. 2011. Production of KPC-2 carbapenemase by an *Escherichia coli* clinical isolate belonging to the international ST131 clone. *Antimicrob. Agents Chemother.* 55:4935–4936.
  47. Naas T, Cuzon G, Gaillot O, Courcol R, Nordmann P. 2011. When carbapenem-hydrolyzing  $\beta$ -lactamase KPC meets *Escherichia coli* ST131 in France. *Antimicrob. Agents Chemother.* 55:4933–4934.
  48. Peirano G, Schreckenberger PC, Pitout JD. 2011. Characteristics of NDM-1-producing *Escherichia coli* isolates that belong to the successful and virulent clone ST131. *Antimicrob. Agents Chemother.* 55:2986–2988.
  49. Cullik A, Pfeifer Y, Prager R, von Baum H, Witte W. 2010. A novel IS26 structure surrounds *bla*<sub>CTX-M</sub> genes in different plasmids from German clinical *Escherichia coli* isolates. *J. Med. Microbiol.* 59:580–587.
  50. Eckert C, Gautier V, Arlet G. 2006. DNA sequence analysis of the genetic environment of various *bla*<sub>CTX-M</sub> genes. *J. Antimicrob. Chemother.* 57:14–23.
  51. Poirel L, Naas T, Nordmann P. 2008. Genetic support of extended-spectrum beta-lactamases. *Clin. Microbiol. Infect.* 14(Suppl 1):75–81.
  52. Johnson JR, Nicolas-Chanoine MH, DeRoy C, Castanheira M, Robicsek A, Hansen G, Weissman S, Urban C, Platell J, Trott D, Zhanel G, Clabots C, Johnston BD, Kuskowski MA. 2012. Comparison of *Escherichia coli* ST131 pulsotypes, by epidemiologic traits, 1967–2009. *Emerg. Infect. Dis.* 18:598–607.